Skip to main content
Mundipharma's white blood cell booster OK'd in EU

Mundipharma's Pelmeg, or pegfilgrastim, has been approved by European regulators to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients whose malignancies were treated with cytotoxic chemotherapy. The drug is a biosimilar to Amgen's Neulasta.

Full Story: